Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma

Current Opinion in Gastroenterology

Volumn 30, Issue 3, 2014, Pages 295-302

  Grassian, Alexandra R ^a   Pagliarini, Raymond ^a   Chiang, Derek Y ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

differentiation; DNA methylation; epigenetics; tumor metabolism

Indexed keywords

2 HYDROXYGLUTARIC ACID; COLLAGEN; DNA; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; ALPHA-HYDROXYGLUTARATE; GLUTARIC ACID DERIVATIVE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN;

BILE DUCT CARCINOMA; CELL DIFFERENTIATION; DNA METHYLATION; HISTONE METHYLATION; HUMAN; HYPOXIA; MUTATION; NONHUMAN; PHENOTYPE; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; BILE DUCT TUMOR; GENETICS; INTRAHEPATIC BILE DUCT; METABOLISM; PATHOLOGY;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL DIFFERENTIATION; CHOLANGIOCARCINOMA; DNA METHYLATION; GLUTARATES; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION; PROLYL HYDROXYLASES; SIGNAL TRANSDUCTION;

EID: 84898543442     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000050     Document Type: Review

References (50)

1. Andersen JB, Thorgeirsson SS. Genetic profiling of intrahepatic cholangio-carcinoma. Curr Opin Gastroenterol 2012; 28:266-272.
2. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangio-carcinoma. Gastroenterology 2013; 145:1215-1229.
3. Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012; 17:72-79.
4. Wang P, Dong Q, Zhang C, et al. Mutations in isocitrate dehydrogenase1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hyper-methylation targets with glioblastomas. Oncogene 2013; 32:3091-3100.
5. Voss JS, Holtegaard LM, Kerr SE, et al. Molecular profiling of cholangiocar-cinoma shows potential for targeted therapy treatment decisions. Hum Pathol 2013; 44:1216-1222.
6. Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholan-giocarcinomas. Nat Genet 2013; 45:1470-1473.
7. Chan-On W, Nairismägi ML, Ong CK, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and noninfection-related bile duct cancers. Nat Genet 2013; 45:1474-1478.
8. Jang S, Chun SM, Hong SM, et al. High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases. Mod Pathol 2013; 10.1038/modpathol.2013.194.
9. Arai Y, Totoki Y, Hosoda F, et al. FGFR2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 2013; 10.1002/hep.26890.
10. Lee J, van Hummelen P, Go C, et al. High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PLoS ONE 2012; 7:e38892.
11. Wu Y-M, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013; 3:636-647.
12. Gu T, Deng X, Huang F, et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PloS One 2011; 6:e15640.
13. Saborowski A, Saborowski M, Davare MA, et al. Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target. Proc Natl Acad Sci USA 2013; 110:19513-19518.
14. Davare MA, Saborowski A, Eide CA, et al. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proc Natl Acad Sci USA 2013; 110:19519-19524.
15. Andersen JB, Spee B, Blechacz BR, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2012; 142:1021-1031.
16. Sia D, Tovar V, Moeini A, et al. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene 2013; 32:4861-4870.
17. Kipp BR, Voss JS, Kerr SE, et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Human Pathol 2012; 43:1552-1558.
18. Yang H, Ye D, Guan K-L, et al. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res 2012; 18:5562-5571.
19. Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov 2013; 3:730-741.
20. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. New Engl J Med 2009; 360:765-773.
21. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1, 010 diffuse gliomas. Acta Neuropathol 2009; 118:469-474.
22. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 465:739-744.
23. Ward PS, Patel J, Wise DR, et al the common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17:225-234.
24. Loenarz C, Schofield CJ. Expanding chemical biology of 2-oxoglutarate oxygenases. Nat Chem Biol 2008; 4:152-156.
25. Losman J-A, Kaelin WG Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dec 2013; 27:836-852.
26. Jones PA, Baylin SB the epigenomics of cancer. Cell 2007; 128:683-692.
27. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128:693-705.
28. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18:553-567.
29. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011; 19:17-30.
30. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identificationof a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17:510-522.
31. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012; 483:479-483.
32. Duncan CG, Barwick BG, Jin G, et al. A heterozygous IDH1(R132H/WT) mutation induces genome-wide alterations in DNA methylation. Genome Res 2012; 22:2339-2355.
33. Lu C, Venneti S, Akalin A, et al. Induction of sarcomas by mutant IDH2. Genes Dec 2013; 27:1986-1998.
34. Borodovsky A, Salmasi V, Turcan S, et al. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget 2013; 4:1737-1747.
35. Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012; 483:474-478.
36. Sasaki M, Knobbe CB, Munger JC, et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012; 488:656-659.
37. Sasaki M, Knobbe CB, Itsumi M, et al. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dec 2012; 26:2038-2049.
38. Losman J-A, Looper RE, Koivunen P, et al. (R)-2-Hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013; 339:1621-1625.
39. Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013; 340:622-626.
40. Chen C, Liu Y, Lu C, et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dec 2013; 27:1974-1985.
41. Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013; 340:626-630.
42. Grassian AR, Lin F, Barrett R, et al. Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/MicroRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT). J Biol Chem 2012; 287:42180-42194.
43. Losman JA, Kaelin WG Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 2013; 27:836-852.
44. Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1 alpha. Science 2009; 324:261-265.
45. Koivunen P, Lee S, Duncan CG, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012; 483:485-488.
46. King A, Selak MA, Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 2006; 25:4675-4682.
47. Shen C, Kaelin WG Jr the VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol 2013; 23:18-25.
48. Myllyharju J, Kivirikko KI. Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends Genet 2004; 20:33-43.
49. Chaturvedi A, Cruz MMA, Jyotsana N, et al. Mutant IDH1 promotes leuke-mogenesis in vivo and can be specifically targeted in human AML. Blood 2013; 122:2877-2887.
50. Oishi N, Kumar MR, Roessler S, et al. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesench-ymal transition in intrahepatic cholangiocarcinoma. Hepatology 2012; 56: 1792-1803.